Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Equillium, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
EQ
Nasdaq
2830
www.equilliumbio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Equillium, Inc.
Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists
- Apr 8th, 2026 6:30 am
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 2nd, 2026 2:05 pm
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
- Mar 25th, 2026 2:05 pm
Here’s What Roth Capital Thinks of Equillium (EQ) Stock
- Mar 24th, 2026 3:38 pm
Equillium to Participate in the 38th Annual Roth Conference
- Mar 18th, 2026 6:30 am
Equillium Announces $35 Million Financing with RA Capital Management
- Mar 13th, 2026 6:00 am
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference
- Feb 25th, 2026 6:30 am
Equillium Conference: EQ504 Targets Ulcerative Colitis Ahead of Mid-Year Phase 1 Start
- Feb 13th, 2026 11:28 am
Equillium to Participate in Upcoming Investor Conferences
- Nov 20th, 2025 2:35 pm
Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update
- Nov 13th, 2025 2:05 pm
Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025
- Oct 22nd, 2025 6:00 am
Equillium Announces Leadership and Corporate Updates
- Oct 6th, 2025 2:02 pm
Equillium to Participate in the Cantor Global Healthcare Conference 2025
- Aug 29th, 2025 2:03 pm
Trending tickers: Intel, Tilray, monday.com, Equillium and AMC
- Aug 12th, 2025 2:44 am
BC-Most Active Stocks
- Aug 11th, 2025 8:30 am
Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic
- Aug 11th, 2025 6:30 am
Spotlight On 3 Promising Penny Stocks With Over $20M Market Cap
- Aug 4th, 2025 6:04 am
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists
- May 6th, 2025 6:00 am
Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504
- May 1st, 2025 6:00 am
Equillium Announces Feedback from the U.S. Food and Drug Administration
- Apr 24th, 2025 7:00 am
Scroll